Roche will present new data at the Alzheimer’s Association International Conference 2026 (AAIC) in London. The event takes place from July 12 to July 15. Presentations cover the development of next-generation medicines and diagnostic tests.
The company will deliver five oral presentations on trontinemab. These sessions include new long-term data from the Phase Ib/IIa study. Roche will also detail the design of the Phase III PrevenTRON study in preclinical Alzheimer’s disease.
Additional data features the Elecsys pTau217 blood test. This diagnostic tool holds a CE mark for use in primary and secondary care settings.